AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Articles
December 20, 2013

Characterizing mild cognitive impairment in incident Parkinson disease
The ICICLE-PD Study

Alison J. Yarnall, MRCP, PhD, David P. Breen, MRCP, Gordon W. Duncan, MRCP, Tien K. Khoo, MRCP, PhD, Shirley Y. Coleman, PhD, Michael J. Firbank, PhD, Cristina Nombela, PhD, … Show All … , Sophie Winder-Rhodes, PhD, Jonathan R. Evans, MRCP, PhD, James B. Rowe, MRCP, PhD, Brit Mollenhauer, MD, Niels Kruse, PhD, Gavin Hudson, PhD, Patrick F. Chinnery, MRCP, PhD, John T. O’Brien, FRCPsych, DM, Trevor W. Robbins, PhD, Keith Wesnes, PhD, David J. Brooks, MD, DSc, Roger A. Barker, MRCP, PhD, David J. Burn, FRCP, MD, and On behalf of the ICICLE-PD Study GroupAuthors Info & Affiliations
January 28, 2014 issue
82 (4) 308-316
https://doi.org/10.1212/WNL.0000000000000066
Letters to the Editor
Track CitationsAdd to favorites
Get Access

Abstract

Objective:

To describe the frequency of mild cognitive impairment (MCI) in Parkinson disease (PD) in a cohort of newly diagnosed incident PD cases and the associations with a panel of biomarkers.

Methods:

Between June 2009 and December 2011, 219 subjects with PD and 99 age-matched controls participated in clinical and neuropsychological assessments as part of a longitudinal observational study. Consenting individuals underwent structural MRI, lumbar puncture, and genotyping for common variants of COMT, MAPT, SNCA, BuChE, EGF, and APOE. PD-MCI was defined with reference to the new Movement Disorder Society criteria.

Results:

The frequency of PD-MCI was 42.5% using level 2 criteria at 1.5 SDs below normative values. Memory impairment was the most common domain affected, with 15.1% impaired at 1.5 SDs. Depression scores were significantly higher in those with PD-MCI than the cognitively normal PD group. A significant correlation was found between visual Pattern Recognition Memory and cerebrospinal β-amyloid 1–42 levels (β standardized coefficient = 0.350; p = 0.008) after controlling for age and education in a linear regression model, with lower β-amyloid 1–42 and 1–40 levels observed in those with PD-MCI. Voxel-based morphometry did not reveal any areas of significant gray matter loss in participants with PD-MCI compared with controls, and no specific genotype was associated with PD-MCI at the 1.5-SD threshold.

Conclusions:

In a large cohort of newly diagnosed PD participants, PD-MCI is common and significantly correlates with lower cerebrospinal β-amyloid 1–42 and 1–40 levels. Future longitudinal studies should enable us to determine those measures predictive of cognitive decline.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

Supplementary Material

File (co_investigators.docx)
File (coinvestigators.docx)
File (e-methods.docx)
File (emethods.docx)
File (table1.docx)
File (table2.docx)
File (table_3.docx)
File (table_e-1.docx)
File (table_e-2.docx)
File (table_e-3.docx)

REFERENCES

1.
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837–844.
Crossref
PubMed
Google Scholar
2.
Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:585–589.
Crossref
PubMed
Google Scholar
3.
Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 2009;73:1469–1477.
Crossref
PubMed
Google Scholar
4.
Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958–2969.
Crossref
PubMed
Google Scholar
5.
Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349–356.
Crossref
PubMed
Google Scholar
6.
Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343–1349.
Crossref
PubMed
Google Scholar
7.
Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013;70:580–586.
Crossref
PubMed
Google Scholar
8.
Weintraub D, Dietz N, Duda JE, et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 2012;135:170–180.
Crossref
PubMed
Google Scholar
9.
Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055–1061.
Crossref
PubMed
Google Scholar
10.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
Crossref
PubMed
Google Scholar
11.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.
Crossref
PubMed
Google Scholar
12.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
Crossref
PubMed
Google Scholar
13.
Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983;17:37–49.
Crossref
Google Scholar
14.
Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
Crossref
PubMed
Google Scholar
15.
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699.
Crossref
PubMed
Google Scholar
16.
Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183–192.
Crossref
PubMed
Google Scholar
17.
Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994;5:266–281.
PubMed
Google Scholar
18.
Benton AL. Differential behavioural effects of frontal lobe disease. Neuropsychologia 1968;6:53–60.
Crossref
Google Scholar
19.
Goodglass H. The Assessment of Aphasia and Related Disorders. Philadelphia: Lea & Febiger; 1972.
Google Scholar
20.
Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:483–488.
Crossref
PubMed
Google Scholar
21.
Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062–1069.
Crossref
PubMed
Google Scholar
22.
Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272–1277.
Crossref
PubMed
Google Scholar
23.
Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011;26:629–636.
Crossref
PubMed
Google Scholar
24.
Poletti M, Frosini D, Pagni C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:601–606.
Crossref
PubMed
Google Scholar
25.
Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G; Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009;72:1121–1126.
Crossref
PubMed
Google Scholar
26.
Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK: the CamPaIGN study. Brain 2004;127:550–560.
Crossref
PubMed
Google Scholar
27.
Bronnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP. Verbal memory in drug-naive, newly diagnosed Parkinson's disease: the retrieval deficit hypothesis revisited. Neuropsychology 2011;25:114–124.
Crossref
PubMed
Google Scholar
28.
Lashley T, Holton JL, Gray E, et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008;115:417–425.
Crossref
PubMed
Google Scholar
29.
Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407–411.
Crossref
PubMed
Google Scholar
30.
Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24:2203–2210.
Crossref
PubMed
Google Scholar
31.
Montine TJ, Shi M, Quinn JF, et al. CSF Abeta (42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682–2685.
Crossref
PubMed
Google Scholar
32.
Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22:200–208.
Crossref
PubMed
Google Scholar
33.
Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81:1080–1086.
Crossref
PubMed
Google Scholar
34.
Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64:850–855.
Crossref
PubMed
Google Scholar
35.
Adler CH, Caviness JN, Sabbagh MN, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:827–828.
Crossref
PubMed
Google Scholar
36.
Reesink FE, Lemstra AW, van Dijk KD, et al. CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 2010;22:87–95.
Crossref
PubMed
Google Scholar
37.
El-Agnaf OM, Walsh DM, Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol 2003;2:461–462.
Crossref
PubMed
Google Scholar
38.
Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012;27:512–518.
Crossref
PubMed
Google Scholar
39.
Melzer TR, Watts R, MacAskill MR, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:188–194.
Crossref
PubMed
Google Scholar
40.
Dalaker TO, Zivadinov R, Larsen JP, et al. Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord 2010;25:629–633.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 82 • Number 4 • January 28, 2014
Pages: 308-316
PubMed: 24363137

Copyright

© 2014 American Academy of Neurology.

Publication History

Received: July 12, 2013
Accepted: October 11, 2013
Published online: December 20, 2013
Published in print: January 28, 2014

Permissions

Request permissions for this article.

Disclosure

A. Yarnall is supported by grants from the Lockhart Parkinson's Disease Research Fund and MJFF. She has received honoraria from Teva-Lundbeck and sponsorship from Teva-Lundbeck, UCB, GlaxoSmithKline, Genus, and AbbVie for attending conferences. D. Breen is supported by a grant from Big Lottery Fund/Parkinson's UK, has received a Raymond and Beverly Sackler Studentship, and received honoraria from UCB. G. Duncan is supported by a grant from the Lockhart Parkinson's Disease Fund and has received sponsorship from UCB and Abbott for attending conferences. T. Khoo has received honoraria and educational grants from Teva-Lundbeck and Hospira and sponsorship from GSK and UCB for attending conferences. S. Coleman, M. Firbank, and C. Nombela report no disclosures. S. Winder-Rhodes is supported by a Merck Sharp and Dohme Studentship. J. Evans has received honoraria from UCB. J. Rowe is supported by the Wellcome Trust (088324), Medical Research Council, NIHR, Parkinson's UK, Evelyn Trust, and James S. McDonnell Foundation. B. Mollenhauer has received honoraria from Teva Pharmaceuticals, Orion Corporation, and GSK. She is an associate editor for the Journal of Alzheimer's Disease. She holds or has pending patents re: method of differentially diagnosing dementias; novel ELISA-based quantification of α-synuclein proteins in CSF and peripheral blood products using 384-well plates; and microRNA expression profiling of CSF. She serves as a consultant for Bayer Schering Pharma AG and receives research support from Teva Pharmaceutical Industries Ltd., Desitin Pharmaceuticals, GmbH, Boehringer Ingelheim, GE Healthcare, MJFF, the American Parkinson's Disease Association, and the Stifterverband für die Deutsche Wissenschaft (Dr. Werner Jackstädt-Stipend). N. Kruse reports no disclosures. G. Hudson is supported by a Parkinson's UK Senior Fellowship. P. Chinnery is a Wellcome Trust Senior Fellow in Clinical Science and a UK NIHR Senior Investigator. He receives additional support from the Wellcome Trust Centre for Mitochondrial Research, the Medical Research Council Centre for Translational Muscle Disease research, the Association Française contre les Myopathies, and EU FP7 TIRCON, and the NIHR Newcastle Biomedical Research Centre. J. O'Brien has acted as consultant for GE Healthcare and TauRx, and has been on the advisory board for Lilly, Novartis, and Nutricia. He has received grants from Lilly and received honoraria from GE Healthcare and Novartis. T. Robbins consults for Cambridge Cognition and receives royalties for CANTAB. He also consults for Lilly, GSK, Merck, Sharp & Dohme, Shire Pharmaceuticals, Lundbeck, and Teva, and has been in receipt of recent research grants from Lilly, GSK, and Lundbeck. K. Wesnes has for the last 3 years been an employee of Bracket, a division of United BioSource Corporation, which provides services to the clinical trial industry for numerous pharmaceutical companies. D. Brooks is a consultant for GE Healthcare, Shire Pharmaceuticals, and Cytox plc. He has received grants from the EU FP7 programme, MJFF, Medical Research Council, Parkinson's UK, Alzheimer Research UK, Lundbeck Foundation, Danish Council for Independent Research, and GE Healthcare. R. Barker has received grants from NIHR, Wellcome Trust, Cure-PD, Parkinson's UK, Rosetrees Trust, EU-FP7 programme, Evelyn Trust, and MJFF. He has received honoraria from Teva-Lundbeck and GSK in the past 2 years and is co–editor-in-chief for the Archives of Clinical Neuroscience and Rehabilitation and Journal of Neurology and associate editor for the Journal of Parkinson's Disease. D. Burn has received grants from NIHR, Wellcome Trust, GSK Ltd., Parkinson's UK, and MJFF. He has received honoraria from Teva-Lundbeck and UCB in the past 2 years and acted as consultant for GSK and Archimedes. Go to Neurology.org for full disclosures.

Study Funding

The authors acknowledge the study funders, Parkinson's UK, Lockhart Parkinson's Disease Research Fund, and Michael J. Fox Foundation (MJFF). The research was supported by the NIHR Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust/Newcastle University, and an NIHR Biomedical Research Centre award to the University of Cambridge/Addenbrooke's Hospital. Newcastle University and the University of Cambridge acknowledge the support of the NIHR, through the Dementias and Neurodegenerative Diseases Research Network. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Authors

Affiliations & Disclosures

Alison J. Yarnall, MRCP, PhD*
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Received travel funds from TEVA-Lundbeck for attending a conference. (2) Received travel funds from UCB for attending a conference. (3) Received speaker honoraria from TEVA-lundbeck. (4) Received travel funds from Genus for attending a conference. (5) Received travel funds from Abbott for attending a conference.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Michael J Fox Foundation (2) Lockhart Newcastle University fund (3) Parkinson's UK (J-0802)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David P. Breen, MRCP*
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1. UCB Pharma, speaker fee
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
1. University of Cambridge, Clinical Research Fellow in Neurology 2. Barking Havering and Redbridge NHS Trust, Honorary SpR in Neurology
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1. Parkinson's UK
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Gordon W. Duncan, MRCP*
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1) Parkinson's UK (Grant reference number J-0802), (2) Lockhart Parkinson's Disease Fellowship
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Tien K. Khoo, MRCP, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Teva-Lundbeck, speaker honoraria Hospira, speaker honoraria Teva-Lundbeck, educational grant UCB Pharma and GSK, travel grant
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Shirley Y. Coleman, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Informa, contribution to travel expenses to speak at meeting Process Validation 22nd � 23rd November 2011 Andels Hotel Berlin, Germany
Editorial Boards:
1.
Quality Technology and Quantitative Management, Associate Editor, from 2008 to present Total Quality Management, Associate Editor, 2006 to present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Newcastle University, Principal Research Associate
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michael J. Firbank, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Cristina Nombela, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Sophie Winder-Rhodes, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Merck Sharp and Dohme PhD studentship
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jonathan R. Evans, MRCP, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) UCB pharma, speaker honoraria, (2) Genuspharma, travel and conference fees
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Glaxo-Smithkline
Speakers' Bureaus:
1.
UCB pharma
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
James B. Rowe, MRCP, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
2013 Montreal Neurological Institute, honorarium for lecture 2012-2013 Wellcome Trust fellowship, 088324, research support
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
2012-2013 Medical Research Council, MC-A060-5PQ30,research support
Research Support, Academic Entities:
1.
2012-2013 Wellcome Trust fellowship 2012-2013 National Institute for Health Research
Research Support, Foundations and Societies:
1.
2012-2013 James F McDonnell Foundation 2013 - Evelyn Trust
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Brit Mollenhauer, MD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Speaker honoraria from orion Corporation and GlaxoSmithKline; received funding for travels from GlaxoSmithKline horiraria for teaching presentations at orion Corporation, Teva Pharmaceutical Industries Ttd.
Editorial Boards:
1.
associate Editor for the Journal of Alzheimer Disease
Patents:
1.
patent WO2008058760 (method of differentially diagnosed Dementias) pending 6612-60001 (novel ELISA-based quantification of alpha-synuclein proteins in cerebrospinal fluid and peripheral blood products using 284-well plates) and 7570/17300PC (microRNA expression profiling of cerebrospinal fluid)
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultant of Bayer Schering Pharma AG
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Teva Pharmaceutical Industries Ltd., Desitin Pharmaceuticals, Boehringer INgelheim, GE Healthcare
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
The Michael J. Fox Foundation for Parkinson's Research The Americal Parknson's Disease Association Stifterverband f�r die Deutsche Wissenschaft (Dr. Werner Jackst�dt-Stipend)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Niels Kruse, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Gavin Hudson, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Patrick F. Chinnery, MRCP, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
BRAIN, Associate Editor 2004
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Medical Research Council (UK)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Wellcome Trust
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
John T. O’Brien, FRCPsych, DM
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
(1) TAURx (2) Cytox
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Pfizer, speaker honoraria (2) GE Healthcare, speaker honoraria (3) Eisai, speaker honoraria (4) Shire, speaker honoraria (5) Lundbeck, speaker honoraria (6) Lilly, speaker honoraria (7) Novartis, speaker honoraria
Editorial Boards:
1.
(1) Psychological Medicine, Editorial Board (2) International Psychogeriatrics, Deputy Editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) GE Healthcare (2) Bayer Healthcare (3) Lilly
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Lilly
Research Support, Government Entities:
1.
(1) Parkinson�s Disease Society 01.10.2007-30.09.2010; (2) Sir Jules Thorn Charitable Trust, 01.02.2006-31.01.2011; (3) DoH/Wellcome Trust, 01.06.2006-31.05.2011; (4) Medical Research Council, 01.11.2007-31.12.2013; (5) Parkinson's Disease Society, 01.02.2009-31.01.2014; (6) Member of the NIHR College of Senior Investigators, 01.04.2009-31.03.2014; (7) NIHR, 01.03.2010-28.02.2013; (8) Wellcome Trust Intermediate Fellowship, 01.05.2010-30.04.2013; (9) NIHR-RfPB, 01.08.2010-31.07.2012. (10) The Food Standards Agency, 01.12.2010-31.07.2013. (11) BUPA/Alzheimer's Society, 01.12.2010-30.11.2012. (12) British Heart Foundation/The Stroke Association, 01.01.2011-31.12.2015. (13) HTA, 01.03.2011-30.04.2014. (14) Alzheimer's Research Trust, 01.03.2011-31.08.2012.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Trevor W. Robbins, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
(1) Lilly (1) Lundbeck
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Lilly, Lundbeck, Shire, Teva - travel expenses (2) ECNP - travel expenses
Editorial Boards:
1.
Psychopharmacology, field editor since 1980. Honorarium.
Patents:
1.
NONE
Publishing Royalties:
1.
Oxford University Press, Neurobiology of Addiction (2009), Decision Making Affect and Learning (co-editor) (2011)
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Cambridge Cognition, Lilly, Lundbeck, Shire, Teva, Chempartners, GSK
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Lilly, Lundbeck, GSK
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
Cambridge Cognition CANTAB
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Keith Wesnes, PhD
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
I am an employee and stockholder in Bracket which provides services to the clinical trial industry
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
I hold stock in the company which employs me
Legal Proceedings:
1.
NONE
View all articles by this author
David J. Brooks, MD, DSc
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
Member of Alzheimer UK Molecular Science Advisory Board
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Honoraria from GlaxoSmithKline, Genzyme, TEVA, Merck for attending ABs.
Editorial Boards:
1.
Associate Editor of Brain. Editorial board member of Synapse, Basal Ganglia, J Parkinson's Disease, Parkinsonism and related disorders, Clin Neurol and Neurosur, Neurotherapeutics, Molecular Imaging and Biology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Shire Pharmaceuticals, GE Healthcare
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
GE Healthcare
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
GE Healthcare
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
GE Healthcare
Stock/stock Options, Medical Equipment & Materials:
1.
GE Healthcare
Legal Proceedings:
1.
NONE
View all articles by this author
Roger A. Barker, MRCP, PhD‡
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
Teva Lundbeck, UK.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Teva Lundbeck, Positive steps Meetings 2010, 2011, 2012. MDS Meeting Toronto 2011, Dublin 2012.
Editorial Boards:
1.
Co-Editor in Chief, Journal of Neurology. Editorial Boaard of Journal of Parkinson's Disease; Synapse; Regenerative Medicine.
Patents:
1.
NONE
Publishing Royalties:
1.
Neuroscience at a glance. 5th Edition. 2012.Wiley.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
I have recieved funding from the EU; Parkinson's UK; CHDI; Cure PD; Rosetrees trust; Michael J Fox Foundation.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David J. Burn, FRCP, MD‡
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Teva-Lundbeck: payment for speaking / chairing annual meetings in 2010-2013 in UK UCB: speaker at national meetings 2010-2013
Editorial Boards:
1.
Movement Disorder Journal: Associate Editor (1st Jan 2010-present)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
GSK in 2011-2012(payment made to Newcastle University)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Multicentre UK Study of the acetylcholinesterase inhibitor donepezil in early dementia associated with Parkinson's disease (MUSTARDD-PD). NIHR Health Technology Assessment Programme Project REF: 08/14/13: 1st Sept 2010 � 31st Aug 2015; (Burn DJ, Barker RA, Braithwaite B, Burns A, Clarke CE, Hindle JV, Knapp M, Lees AJ, Leroi I, McColl E, McKeith IG, O�Brien JT, Steen IN, Wheatley K). A Biomedical Research Unit in Lewy Body Dementia. NIHR: 1st April 2012 - 31st March 2017; (Burn DJ, McKeith IG, O�Brien JT, Kirkwood TBL, Chinnery PF, Ford GA).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Parkinson's UK: Visual symptoms in Parkinson�s disease and Parkinson�s disease dementia: Association with ocular and retinal pathology, visuo-perceptual deficits and impact on daily living and quality of life. Parkinson�s UK: November 2007-October 2010; (Archibald N, Mosimann UP, Clarke MP, Burn DJ). Predicting Dementia in Parkinson�s disease: A genotypic and phenotypic study (ICICLE-PD). Parkinson�s UK REF J0802, UK: October 2007 � September 2012; (Burn DJ, Barker RA, Brooks DJ, O�Brien JT, McKeith IG, Chinnery PF, Owen AM, Brayne CEG, Robbins T, Sawcer S, Coleman S). The Parkinson�s Repository of Biomarkers and Networked Datasets (PROBAND) programme: A UK national clinical consortium linking novel biomarker research to clinical expression, and progression rates, in Parkinson�s disease. Parkinson�s UK: 2011-2015; (Grosset D, Burn DJ, Barker RA, Ben-Shlomo Y, Bajaj N, Hardy J, Wood NW, Morris HR). Apomorphine: A modifier of amyloid deposition in Parkinson�s disease? Parkinson�s UK REF K-1101: October 2011 - April 2012;(Burn DJ, Revesz T, Lees AJ). Michael J Fox Foundation Clinical trial to compare cognitive scales. Michael J Fox Foundation: 1st October 2011 - 30th September 2016; (Burn DJ, Weintraub D). Predicting cognitive profiles in Parkinson�s disease: A multimodal approach. Michael J Fox Foundation: 1st November 2011 - 31st October 2013; (Burn DJ, Rochester L, O�Brien JT, Coleman SY, Baker MR).
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
On behalf of the ICICLE-PD Study Group
From the Institute for Ageing and Health (A.J.Y., G.W.D., M.J.F., D.J.B.), Industrial Statistics Research Unit (S.Y.C.), and Institute of Genetic Medicine (G.H., P.F.C.), Newcastle University; John van Geest Centre for Brain Repair (D.P.B., J.R.E., R.A.B.), Department of Clinical Neurosciences (C.N., S.W.-R., J.B.R.), Behavioural and Clinical Neuroscience Institute (C.N., S.W.-R., J.B.R., T.W.R.), MRC Cognition and Brain Sciences Unit (C.N., S.W.-R., J.B.R.), Departments of Psychiatry (J.T.O.) and Psychology (T.W.R.), University of Cambridge, UK; School of Medicine (T.K.K.), Griffith University, Australia; Paracelsus-Elena-Klinik (B.M.), Kassel, and Göttingen University; Institute for Neuropathology (N.K.), Prion and Dementia Research Unit, University Medical Centre Göttingen, Germany; Centre for Human Psychopharmacology (K.W.), Swinburne University, Melbourne, Australia; and Department of Medicine (D.J.W.), Imperial College London, UK.

Notes

Correspondence to Prof. Burn: [email protected]
*
These authors contributed equally to this work.
‡
These authors contributed equally to this work.
ICICLE-PD Study Group coinvestigators are listed on the Neurology® Web site at www.neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Dr. Yarnall, Dr. Breen, and Dr. Duncan were involved with coordination of the study. They were also involved with participant recruitment, clinical assessment, data collection, and statistical analysis, and they drafted the manuscript. Dr. Khoo was involved with the study design and coordination of the study. He was also involved with participant recruitment, clinical assessment, data collection, and manuscript revision. Dr. Coleman was involved with statistical analysis and reviewed the manuscript. Dr. Firbank was involved with MRI data analysis and reviewed the manuscript. Dr. Nombela was involved with data acquisition and reviewed the manuscript. Dr. Winder-Rhodes was involved with data acquisition and reviewed the manuscript. Dr. Evans was involved in data acquisition and reviewed the manuscript. Dr. Rowe was involved with data acquisition and reviewed the manuscript. Prof. Mollenhauer is a principal investigator. She analyzed the CSF samples and reviewed and approved the final manuscript. Dr. Kruse analyzed the CSF samples and reviewed and approved the final manuscript. Dr. Hudson analyzed the DNA samples and reviewed and approved the final manuscript. Prof. Chinnery is a principal investigator. He analyzed the DNA samples and reviewed and approved the final manuscript. Prof. O’Brien is a principal investigator and coapplicant for the funding grant. He was involved in the study supervision and reviewed and approved the final manuscript. Prof. Robbins is a principal investigator, was involved in the study design, and reviewed the manuscript. Prof. Wesnes is a principal investigator, was involved in the study design and statistical analysis, and reviewed the manuscript. Prof. Brooks is a principal investigator and coapplicant for the main funding grant. He was also involved with the study design and reviewed the manuscript. Prof. Barker is a principal investigator and coapplicant for the main funding grant. He was involved with the study design and reviewed the manuscript. Prof. Burn is the chief investigator and main applicant for the funding grant. He was involved with the study design, supervised the study, and reviewed the manuscript.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Cinzia Palmirotta,
    • Simona Aresta,
    • Petronilla Battista,
    • Serena Tagliente,
    • Gianvito Lagravinese,
    • Davide Mongelli,
    • Christian Gelao,
    • Pietro Fiore,
    • Isabella Castiglioni,
    • Brigida Minafra,
    • Christian Salvatore,
    Unveiling the Diagnostic Potential of Linguistic Markers in Identifying Individuals with Parkinson’s Disease through Artificial Intelligence: A Systematic Review, Brain Sciences, 14, 2, (137), (2024).https://doi.org/10.3390/brainsci14020137
    Crossref
    • Yue Jiao,
    • Zaichao Liu,
    • Juan Li,
    • Yan Su,
    • Xianwen Chen,
    Knowledge mapping of freezing of gait in Parkinson’s disease: a bibliometric analysis, Frontiers in Neuroscience, 18, (2024).https://doi.org/10.3389/fnins.2024.1388326
    Crossref
    • Pedro Renato Brandão,
    • Danilo Assis Pereira,
    • Talyta Cortez Grippe,
    • Diógenes Diego de Carvalho Bispo,
    • Fernando Bisinoto Maluf,
    • Ricardo Titze-de-Almeida,
    • Brenda Macedo de Almeida e Castro,
    • Renato Puppi Munhoz,
    • Maria Clotilde Henriques Tavares,
    • Francisco Cardoso,
    Mapping brain morphology to cognitive deficits: a study on PD-CRS scores in Parkinson’s disease with mild cognitive impairment, Frontiers in Neuroanatomy, 18, (2024).https://doi.org/10.3389/fnana.2024.1362165
    Crossref
    • Miriam R. Rafferty,
    • Erin R. Foster,
    • Angela C. Roberts,
    • Kevin A. Smaller,
    • Lynn L. Johnson,
    • Rachael A. Lawson,
    Stemming the Tide: The Proactive Role of Allied Health Therapy in Parkinson’s Disease, Journal of Parkinson's Disease, 14, s1, (S7-S19), (2024).https://doi.org/10.3233/JPD-230267
    Crossref
    • Rónán O’Caoimh,
    • Mary J. Foley,
    • Suzanne Timmons,
    • D. William Molloy,
    Screening for Cognitive Impairment in Movement Disorders: Comparison of the Montreal Cognitive Assessment and Quick Mild Cognitive Impairment Screen in Parkinson’s Disease and Lewy Body Dementia, Journal of Alzheimer's Disease Reports, 8, 1, (971-980), (2024).https://doi.org/10.3233/ADR-230207
    Crossref
    • Qingrong Ouyang,
    • Lei Xu,
    • Yunwei Zhang,
    • Luwen Huang,
    • Linlin Li,
    • Ming Yu,
    Nonlinear Relationship Between Homocysteine and Mild Cognitive Impairment in Early Parkinson’s Disease: A Cross-Sectional Study, Neuropsychiatric Disease and Treatment, Volume 20, (913-921), (2024).https://doi.org/10.2147/NDT.S460938
    Crossref
    • 金成 廖,
    Research and Progress of Noninvasive Vagus Nerve Stimulation in Parkinson’s Disease, Advances in Clinical Medicine, 14, 01, (1741-1751), (2024).https://doi.org/10.12677/ACM.2024.141249
    Crossref
    • Tamara Schejter‐Margalit,
    • Noam Ben Binyamin,
    • Avner Thaler,
    • Inbal Maidan,
    • Jesse M. Cedarbaum,
    • Avi Orr‐Urtreger,
    • Mali Gana Weisz,
    • Orly Goldstein,
    • Nir Giladi,
    • Anat Mirelman,
    • Rachel Kizony,
    Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers , European Journal of Neurology, 31, 8, (2024).https://doi.org/10.1111/ene.16327
    Crossref
    • Thomas F. Tropea,
    • Whitney Hartstone,
    • Noor Amari,
    • Dylan Baum,
    • Jacqueline Rick,
    • Eunran Suh,
    • Hanwen Zhang,
    • Rachel A. Paul,
    • Noah Han,
    • Rebecca Zack,
    • Eliza M. Brody,
    • Isabela Albuja,
    • Justin James,
    • Meredith Spindler,
    • Andres Deik,
    • Whitley W. Aamodt,
    • Nabila Dahodwala,
    • Ali Hamedani,
    • Aaron Lasker,
    • Howard Hurtig,
    • Matthew Stern,
    • Daniel Weintraub,
    • Pavan Vaswani,
    • Allison W. Willis,
    • Andrew Siderowf,
    • Sharon X. Xie,
    • Vivianna Van Deerlin,
    • Alice S. Chen-Plotkin,
    Genetic and phenotypic characterization of Parkinson’s disease at the clinic-wide level, npj Parkinson's Disease, 10, 1, (2024).https://doi.org/10.1038/s41531-024-00690-6
    Crossref
    • Benjamin J. Whittle,
    • Osagie G. Izuogu,
    • Hannah Lowes,
    • Dasha Deen,
    • Angela Pyle,
    • Jon Coxhead,
    • Rachael A. Lawson,
    • Alison J. Yarnall,
    • Michael S. Jackson,
    • Mauro Santibanez-Koref,
    • Gavin Hudson,
    Early-stage idiopathic Parkinson’s disease is associated with reduced circular RNA expression, npj Parkinson's Disease, 10, 1, (2024).https://doi.org/10.1038/s41531-024-00636-y
    Crossref
  11. See more

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share

View full text|Download PDF